Syra Health Corp (SYRA) Fair Value & Analysis
Healthcare · US · Market cap $6.9M
Syra Health Corp
SYRA · US
Fair value as of: Jul 21, 2026
From 1 valuation models · updated 20 days ago
Share price −8.8% over the past month.
Below-average quality, and screening another 80% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case ($0.1615). The favourable scenario is already priced in.
- Weak quality (41/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range ($0.0850 to $0.1615) leaves room in how you read the outcome.
Price vs Fair Value (3 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 21, 2026.
How to read this chart
34‑month range $0.0521 – $4.85 · fair‑value band $0.0850 – $0.1615 · the $0.6400 price screens above the $0.1275 fair value. Dashed = 300-day average. As of Jul 21, 2026.
Analysis
Syra Health Corp (SYRA) currently trades at $0.6400, while our model-based Fair Value estimate is $0.1275, implying the stock looks roughly 80.1% overvalued today. The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Syra Health Corp generated revenue of $7.6M at a net margin of -2.4%. Revenue grew 22.4% year over year. It earns a return on equity of -7.6%. The balance sheet holds a net cash position of $1.5M. Fundamentals as of Jul 21, 2026
Our scenario range runs from $0.0850 (bear case) to $0.1615 (bull case); at $0.6400, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 9% below its 52-week high. For context, the median of 10 Healthcare peers we cover trades at 11% fair-value upside, at -80%, SYRA screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when SYRA reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 21, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 46 · Market factors (momentum, volatility) 67
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Syra Health Corp., a healthcare services company, provides solutions in behavioral and mental health, population health, digital health, health education and training, and healthcare workforce development and staffing in the United States.
Full company description
Syra Health Corp., a healthcare services company, provides solutions in behavioral and mental health, population health, digital health, health education and training, and healthcare workforce development and staffing in the United States. The company offers Syrenity, a behavioral and mental health application that identifies and prevents the progression of negative factors that can influence individuals' mental health by offering targeted assignments, education, and monitoring symptoms, as well as providing interventions, such as cognitive behavioral therapy and mindfulness techniques; digital health products, including SyraBot, a chatbot to foster connectivity and engagement throughout individuals' care journeys offering members access to necessary information via its AI-powered customer support chat system; and CarePlus, an electronic medical records solution for small to mid-sized healthcare organizations. It also provides analytics as a service, analytics as a service, epidemiology, and health equity analytics solutions. In addition, the company offers medical communications, patient education, and healthcare training; and recruits nurses and allied health professionals for long-term fixed contract positions at hospitals and healthcare facilities. It serves mental health hospitals and organizations, including government agencies, integrated health networks, managed care entities, and pharmaceutical manufacturers. The company was incorporated in 2020 and is headquartered in Carmel, Indiana.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Syra Health Corp reported revenue of $7.2M in FY2025 versus $1.4M in FY2021, a compound +50.5%/yr. Reported net income was −$896K in FY2025.
SYRA screens 80% overvalued. Compare with HCA Healthcare, Inc →
Peer Group
Medical Care Facilities · 261 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $378.85 | $554.93 | +46% |
| Fresenius SE FRE | €41.73 | €32.15 | -23% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.58 SGD | 1.44 SGD | -44% |
| Tenet Healthcare Corporation THC | $194.91 | $338.05 | +73% |
| Rede D'Or São Luiz S.A RDOR3 | R$36.01 | R$47.31 | +31% |
| DaVita Inc DVA | $231.61 | $255.97 | +11% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,955 | ₹2,955 | -67% |
| Fresenius Medical Care AG FMS | $24.68 | $45.60 | +85% |
| Aier Eye Hospital Group 300015 | ¥8.68 | ¥7.67 | -12% |
Compare Syra Health Corp with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Syra Health Corp (SYRA) overvalued or undervalued?
What is the fair value of SYRA?
What is the quality score of SYRA?
What is the revenue of Syra Health Corp (SYRA)?
What is the net profit margin of SYRA?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Syra Health Corp and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.